Bender Robert & Associates Has Cut Vipshop Hldgs LTD (VIPS) Stake By $23.41 Million; Urogen Pharma Limited Ord (URGN) Shorts Down By 29.59%

February 19, 2018 - By Winifred Garcia

Urogen Pharma Limited Ord (NASDAQ:URGN) had a decrease of 29.59% in short interest. URGN’s SI was 183,000 shares in February as released by FINRA. Its down 29.59% from 259,900 shares previously. With 191,300 avg volume, 1 days are for Urogen Pharma Limited Ord (NASDAQ:URGN)’s short sellers to cover URGN’s short positions. The stock decreased 4.31% or $2.16 during the last trading session, reaching $47.92. About 114,841 shares traded. Urogen Pharma Ltd. (NASDAQ:URGN) has 0.00% since February 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Bender Robert & Associates decreased Vipshop Hldgs Ltd (VIPS) stake by 83.93% reported in 2017Q3 SEC filing. Bender Robert & Associates sold 154,032 shares as Vipshop Hldgs Ltd (VIPS)’s stock rose 10.03%. The Bender Robert & Associates holds 29,490 shares with $4.48M value, down from 183,522 last quarter. Vipshop Hldgs Ltd now has $11.88 billion valuation. The stock decreased 0.33% or $0.06 during the last trading session, reaching $18.1. About 7.11M shares traded. Vipshop Holdings Limited (NYSE:VIPS) has risen 27.19% since February 19, 2017 and is uptrending. It has outperformed by 10.49% the S&P500.




Among 20 analysts covering Vipshop Holdings Limited (NYSE:VIPS), 15 have Buy rating, 1 Sell and 4 Hold. Therefore 75% are positive. Vipshop Holdings Limited had 42 analyst reports since August 12, 2015 according to SRatingsIntel. On Tuesday, January 16 the stock rating was upgraded by Bernstein to “Outperform”. The stock of Vipshop Holdings Limited (NYSE:VIPS) earned “Neutral” rating by JP Morgan on Wednesday, February 14. Bank of America upgraded the stock to “Buy” rating in Tuesday, August 16 report. The stock of Vipshop Holdings Limited (NYSE:VIPS) has “Hold” rating given on Thursday, August 17 by Daiwa Securities. Brean Capital maintained Vipshop Holdings Limited (NYSE:VIPS) rating on Thursday, November 19. Brean Capital has “Buy” rating and $17 target. As per Thursday, October 19, the company rating was maintained by KeyBanc Capital Markets. The stock has “Buy” rating by Jefferies on Monday, August 14. JP Morgan downgraded Vipshop Holdings Limited (NYSE:VIPS) rating on Wednesday, May 18. JP Morgan has “Neutral” rating and $11 target. The rating was maintained by Jefferies on Thursday, July 13 with “Buy”. The rating was maintained by KeyBanc Capital Markets on Tuesday, February 13 with “Buy”.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $729.09 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It has a 206.55 P/E ratio. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.